Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Warby Parker logo
Warby ParkerWRBY
$50M0.0%
Schering-Plough logo
Schering-PloughSGP
TTR
Turn Therapeutics Inc.TTRX

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.97B+40.7%
Enterprise value$2.86B+36.8%
P/S4.9×-2.2×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:25 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001819790-26-000064
Line itemJune 30, 2026December 31, 2025
Total liabilities264,410218,732
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 200,000,000 shares authorized; 43,271,347 shares issued and outstanding at June 30, 2026 (unaudited); 42,553,931 shares issued and outstanding at December 31, 202566
Additional paid-in capital799,429769,667
Accumulated other comprehensive income (loss)(557)381
Accumulated deficit(452,146)(426,628)

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s preferred stock, shares authorized?
Tarsus Pharmaceuticals, Inc. (TARS) reported preferred stock, shares authorized of $10M in Q2 2026.
How has Tarsus Pharmaceuticals, Inc.'s preferred stock, shares authorized changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s preferred stock, shares authorized?
Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.
What does preferred stock, shares authorized mean?
Preferred Stock, Shares Authorized

Ask your AI about Tarsus Pharmaceuticals, Inc.'s preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude